TOP HEADLINES

Featured Story

  • Health agencies inform on Zika vaccine timeline

    Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.

NIH-developed dengue vaccine protects all patients in challenge study

As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.

Valneva scores $42M supply contract with DOD

Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.

Health agencies inform on Zika vaccine timeline

Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.

Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market

Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.

Journal walks back 'seriously flawed' study critical of Merck's Gardasil

Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.

MORE NEWS

From Our Sister Sites

FierceMarkets Network
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaAsia
  • FiercePharmaManufacturing
  • FierceCRO
  • FierceDiagnostics
  • FiercePharmaMarketing
  • FierceAnimalHealth
  • More Fierce Network sites
FierceBiotech
Biotech startup trendsetters at Arch hunting up $400M-plus for venture fund

One of the most aggressive investors in bleeding-edge biotechs is gearing up for a new fund, and it's clearly looking to set an in-house record. Arch Venture Partners is gathering $400 million...

FiercePharmaMarketing
NICE changes its tune on J&J's Zytiga for pre-chemo prostate cancer treatment

U.K. cost watchdog the National Institute of Excellence (NICE) has kept a stiff upper lip when it comes to Johnson & Johnson's prostate cancer drug Zytiga, saying that it couldn't fund the med for pre-chemo treatment because it was too expensive. Now J&J has stepped forward with some discounts, so NICE is changing its tune.